Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species

Blood

Volumn 107, Issue 12, 2006, Pages 4714-4720

  Sun, Danyu ^a   McCrae, Keith R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; GELATIN; GLUTATHIONE; LAMININ; MATRIX PROTEIN; PLASMA PROTEIN; POLYPEPTIDE; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; VITRONECTIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; KALLIKREIN KININ SYSTEM; PEROXIDATION; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 33745069060     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3584     Document Type: Article

References (89)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2003;350:2335-2342.
2. Cao Y, Hong A, Schulten H, Post MJ. Update on therapeutic neovascularization. Cardiovasc Res. 2005;65:639-648.
3. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive and proinflammatory attributes. Blood. 1997;90:3819-3843.
4. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood. 1987;70:1-15.
5. Joseph K, Kaplan AP. Formation of bradykinin: a major contributor to the innate inflammatory response. Adv Immunol. 2005;86:159-208.
6. Schiffman S, Mannhalter C, Tyner KD. Human high molecular weight kininogen. J Biol Chem. 1980;255:6433-6438.
7. Morbidelli L, Parenti A, Donnini S, Granger HJ, Ledda F, Ziche M. Differential contribution of bradykinin receptors in angiogenesis. Adv Exp Med Biol. 2000;476:117-128.
8. Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziche M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001;15:1487-1489.
9. Hayashi I, Amano H, Yoshida S, et al. Suppressed angiogenesis in kininogen-deficiencies. Lab Invest. 2002;82:871-880.
10. Zhang J-C, Claffey K, Sakthivel R, et al. Cleaved high molecular weight kininogen promotes endothelial-cell apoptosis and inhibits angiogenesis in vivo. FASEB J. 2000;14:2589-2600.
11. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000;95:543-550.
12. Guo YL, Wang S, Colman RW. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol. 2001;21:1427-1433.
13. Folkman J. Endogenous angiogenesis inhibitors. APMIS. 2004;112:496-507.
14. Wess TJ. Collagen fibril form and function. Adv Protein Chem. 2005;70:341-374.
15. Kiefer J, Alexander A, Farach-Carson MC. Type I collagen mediated changes in gene expression and function of prostate cancer cells. Cancer Treat Res. 2004;118:101-124.
16. Gelse K, Poschl E, Aigner T. Collagens: structure, function and biosynthesis. Adv Drug Deliv Rev. 2003;55:1531-1546.
17. Kalluri R. Basement membranes: structure, assembly and role in tumor angiogenesis. Nat Rev Cancer. 2003;3:422-433.
18. Gullberg DE, Lundgren-Akerlund E. Collagen binding I domain integrins: what do they do? Prog Histochem Cytochem. 2002;37:3-54.
19. Nho RS, Xia H, Kahm J, Kleidon J, Diebold D, Henke CA. Role of integrin-linked kinase in regulating phosphorylation of Akt and fibroblast survival in type I collagen matrices through a beta integrin viability signaling pathway. J Biol Chem. 2005;280:26630-26639.
20. He Y, Chen J, Ren J, Wang G, Guoping C. Type I collagen inhibits hydroxyl radical-induced apoptosis. J Biochem. 2002;132:373-379.
21. Burke-Gaffney A, Callister MEJ, Nakamura H. Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci. 2005;26:398-404.
22. Yatohgo T, Izumi M, Kashiwagi H, Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Function. 1988;13:281-292.
23. Wilkins JA, Li A, Ni H, Stupack DG, Shen C. Control of beta1 integrin function: localization of stimulatory epitopes. J Biol Chem. 1995;271:3046-3051.
24. Arroyo AG, Garcia-Pardo A, Sanchez-Madrid F. A high affinity conformational state on VLA integrin heterodimers induced by an anti-beta 1 chain monoclonal antibody. J Biol Chem. 1993;268:9863-9868.
25. Steinfelder HJ, Quentin I, Ritz V. A fast and sensitive technique to study the kinetics and the concentration dependencies of DNA fragmentation during drug-induced apoptosis. J Pharmacol Toxicol Methods. 2000;43:79-84.
26. Chung C-H, Wu W-B, Huang T-F. Aggretin, a snake venom-derived endothelial integrin a2b1 agonist, induces angiogenesis via expression of vascular endothelial cell growth factor. Blood. 2004;103:2105-2113.
27. Chung C-H, Lu AC, Huang T-F. Molecular cloning and sequence analysis of aggretin, a collagen like platelet aggregation inducer. Biochem Biophys Res Comm. 1999;263:723-727.
28. Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissue. Anal Biochem. 1976;74:214-226.
29. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990;186:407-412.
30. Hirota K, Murata M, Sachi Y, et al. Distinct roles of thioredoxin in the cytoplasm and in the nucleus: a two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem. 1999;274:27891-27897.
31. Shariat-Madar Z, Mahdi F, Schmaier AH. Mapping binding domains of kininogens on endothelial cell cytokeratin 1. J Biol Chem. 1999;274:7137-7145.
32. Hasan AAK, Zisman T, Schmaier AH. Identification of cytokeratin as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A. 1998;95:3615-3620.
33. Joseph K, Ghebrehiwet B, Peerschke EIB, Reid KBM, Kaplan AP. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc Natl Acad Sci U S A. 1996;93:8552-8557.
34. Renne T, Muller-Esterl W. Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett. 2001;500:36-40.
35. Fernando LP, Fernando AN, Joseph K, Kaplan AP. Assessment of the role of heparan sulfate in high molecular weight kininogen binding to human umbilical vein endothelial cells. J Thromb Haemost. 2003;1:2444-2449.
36. Colman RW, Pixley RA, Najamunnisa S, et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2+3 of the urokinase receptor. J Clin Invest. 1997;100:1481-1487.
37. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arth Rheum. 1999;42:1309-1311.
38. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994;269:32380-32388.
39. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science. 1996;273:1551-1555.
40. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type-1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest. 1997;100:58-67.
41. Chavakis T, Kanse SM, Lupu F, et al. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood. 2000;96:514-522.
42. Cao DJ, Guo YL, Colman RW. Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ Res. 2004;94:1227-1234.
43. Stupack DG, Cheresh DA. Apoptotic clues from the extracellular matrix: regulators of angiogenesis. Oncogene. 2003;22:9022-9029.
44. Wattam B, Shang D, Rahman S, et al. Arg-Tyr-Asp (RYD) and Arg-Cys-Asp (RCD) motifs in dendroaspin promote selective inhibition of beta1 and beta3 integrins. Biochem J. 2001;356:11-17.
45. Aoudjit F, Vuori K. Engagment of the a2b1 integrin inhibits Fas ligand expression and activation-induced cell death in T cells in a focal adhesion kinase-dependent manner. Blood. 2000;95:2044-2051.
46. Huang S, Ingber DE. Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. Exp Cell Res. 2000;261:91-103.
47. Ingber DE. Tensegrity: the architectural basis of cellular mechanotransduction. Annu Rev Physiol. 1997;59:575-599.
48. Tan S, Sagara Y, Liu Y, Maher P, Schubert D. The regulation of reactive oxygen species production during programmed cell death. J Cell Biol. 1998;141:1423-1432.
49. Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today. 1994;15:7-10.
50. Tsan MF, Danis EH, del Vecchio PJ, Rosano CL. Enhancement of intracellular glutathione protects endothelial cell against oxidant damage. Biochem Biophys Res Comm. 1985;127:270-276.
51. Zamzami N, Marchetti P, Castedo M, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 1995;182:367-377.
52. Hampton MB, Orrenius S. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett. 1997;414:552-556.
53. Yue TL,Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol. 1997;51:951-962.
54. Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol Lung Mol Physiol. 1989;257:L163-L173.
55. Meister A. Glutathione, ascorbate, and cellular protection. Cancer Res. 1994;54(suppl 7):1969s-1975s.
56. Kwon YW, Masutani H, Nakamura H, Ishii Y, Yodoi J. Redox regulation of cell growth and cell death. Biol Chem. 2003;384:991-996.
57. Imlay JA, Fridovich I. Superoxide production by respiring membranes of Escherichia coli. Free Radical Res Comm. 1991;12-13(Pt 1):59-66.
58. Higuchi Y. Glutathione depletion-induced chromosomal DNA fragmentation associated with apoptosis and necrosis. J Cell Mol Med. 2004;8:455-464.
59. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A. 1997;94:8633-8638.
60. Zhang JC, Qi X, Juarez J, et al. Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. Can J Physiol Pharmacol. 2002;80:85-90.
61. Deshpande SS, Angkeow P, Huang J, Ozani M, Irani K. Rac-1 inhibits TNFa-induced endothelial cell apoptosis: dual regulation by reactive oxygen species. FASEB J. 2000;14:1705-1714.
62. van den Dobblesteen DJ, Noble CS, Schlegel J, Cotgreave IA, Orrenius S, Slater AF. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. J Biol Chem. 1996;271:15420-15427.
63. Li AE, Ito H, Rovira II, et al. A role for reactive oxygen species in endothelial cell anoikis. Circ Res. 1999;85:304-310.
64. Zhang JC, Donate F, Qi X, et al. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci U S A. 2002;99:12224-12229.
65. McDonald NJ, Shivers WY, Narum DL, et al. Endostatin binds tropomyosin: a potential modulator of the antitumor activity of endostatin. J Biol Chem. 2001;276:25190-25196.
66. Guan X, Juarez JC, Shipulina NV, et al. Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost. 2004;92:403-412.
67. Donate F, Juarez JC, Guan X, et al. Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities. Cancer Res. 2004;64:5812-5817.
68. Donaté F, McCrae K, Shaw DE, Mazar AP. Extracellular tropomyosin: a novel common pathway target for anti-angiogenic therapy. Curr Cancer Drug Targets. 2004;4:543-553.
69. Rouslahti E, Reed J. Anchorage independence, integrins and apoptosis. Cell. 1994;77:477-478.
70. Ingber DE, Prusty D, Sun Z, Betensky H, Wang N. Cell shape, cytoskeletal mechanics, and cell cycle control in angiogenesis. J Biomech. 1995;28:1471-1484.
71. Voskoboinik I, Soderholm K, Cotgreave IA. Ascorbate and glutathione homeostasis in vascular smooth muscle cells: cooperation with endothelial cells. Am J Physiol. 1998;275:C1031-C1039.
72. Meister A. Glutathione-ascorbic acid antioxidant system in animals. J Biol Chem. 1994;269:9397-9400.
73. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, Yodoi J. Redox control of cell death. Antioxidant Redox Signal. 2002;4:405-414.
74. Guo YL, Wang S, Cao DJ, Colman RW. Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J Cell Biochem. 2003;89:622-632.
75. Mahdi F, Shariat-Madar Z, Kuo A, Carinato M, Cines DB, Schmaier AH. Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor. J Biol Chem. 2004;279:16621-16628.
76. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem. 1994;269:14746-14750.
77. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol. 2003;200:423-428.
78. Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. J Pathol. 2003;200:465-470.
79. Sottile J. Regulation of angiogenesis by the extracellular matrix. Biochim Biophys Acta. 2004;1654:13-22.
80. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-739.
81. Saitoh M, Nishito H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998;17:2596-2606.
82. Sasada T, Sono H. Thioredoxin/adult T-cell leukemia-derived factor (ADF) and redox regulation. J Toxicol Sci. 1996;21:285-287.
83. Nakamura H, Matsuda M, Furuke K, et al. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol Lett. 1994;42:75-80.
84. Matsuda M, Masutani H, Nakumura H, et al. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J Immunol. 1991;147:3837-3841.
85. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005;65:3967-3979.
86. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin-an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
87. Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem. 2000;275:1209-1215.
88. Maeshima Y, Manfredi M, Reimer C, et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem. 2001;276:15240-15248.
89. Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Curr Opinion Cell Biol. 1998;10:220-231.